Theseus Pharmaceuticals is a technology company.
Theseus Pharmaceuticals has raised $100.0M across 1 funding round.
Theseus Pharmaceuticals has raised $100.0M in total across 1 funding round.
Theseus Pharmaceuticals has raised $100.0M in total across 1 funding round.
Theseus Pharmaceuticals's investors include Advanced Technology Ventures, Atlas Venture, Foresite Capital, General Atlantic, OrbiMed, RA Capital.
Theseus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted oncology therapies to overcome drug resistance in cancer patients.[1][2][3] It specializes in pan-variant kinase inhibitors addressing mutations in key oncogenes like KIT and EGFR, with lead candidates including THE-630 for gastrointestinal stromal tumors (GIST) and THE-349 for non-small cell lung cancer (NSCLC).[1][3] Serving patients with treatment-resistant cancers such as GIST, NSCLC, and chronic myeloid leukemia, Theseus solves the critical problem of drug resistance to tyrosine kinase inhibitors (TKIs), a major barrier in oncology where mutations render standard therapies ineffective.[1][2] With 38 employees based in Cambridge, Massachusetts, the company demonstrated early clinical momentum before entering an acquisition agreement in December 2023.[1][3]
Founded in 2017 in Cambridge, Massachusetts, Theseus Pharmaceuticals emerged to tackle drug resistance in oncology through innovative kinase inhibitor design.[5][6] The company's idea stemmed from recognizing that existing TKIs fail against evolving cancer mutations, prompting a focus on "pan-variant" inhibitors that target both initial oncogenic activations and resistance forms.[1][7] Early traction included advancing THE-630 into clinical development for KIT-driven GIST and building a pipeline with THE-349 for EGFR-mutated NSCLC, culminating in a pivotal 2023 agreement to be acquired by Concentra Biosciences (controlled by Tang Capital Partners) for $3.90–$4.05 per share plus a contingent value right, expected to close in February 2024—with 59% shareholder support.[3]
Theseus rides the wave of precision oncology, where next-generation inhibitors combat resistance—a trend amplified by rising cancer incidence and genomic profiling advances enabling mutation-specific targeting.[1][2] Timing aligns with post-2020 surges in TKI resistance research, as first-line therapies like osimertinib face inevitable mutations, creating demand for fourth-generation solutions like THE-349.[3] Market forces favoring Theseus include a $50B+ global oncology market growing at 8% CAGR, biotech M&A resurgence (e.g., its Concentra deal), and regulatory tailwinds for orphan indications like GIST.[3] By pioneering pan-variant approaches, Theseus influences the ecosystem, pushing competitors toward mutation-agnostic designs and validating acquisition strategies for cash-strapped clinical biotechs.
Post-acquisition by Concentra (likely completed by early 2024), Theseus' pipeline—led by THE-630 and THE-349—gains accelerated funding for Phase 1/2 readouts, potentially yielding proof-of-concept data in 2025–2026.[3] Trends like AI-driven drug design and combo therapies with immunotherapies will shape its path, amplifying impact in resistance-heavy cancers. Its influence may evolve from independent innovator to integrated asset in Concentra's portfolio, driving milestones that validate pan-variant tech across oncology. This positions Theseus as a key player in transforming resistant cancers from dead-ends to treatable conditions, fulfilling its mission to improve patient lives.[1][3]
Theseus Pharmaceuticals has raised $100.0M across 1 funding round. Most recently, it raised $100.0M Series B in April 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2021 | $100.0M Series B | Advanced Technology Ventures, Atlas Venture, Foresite Capital, General Atlantic, OrbiMed, RA Capital |